Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender
Hemogenyx Pharmaceuticals (LSE: HEMO) has announced its decision to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025 and beyond. The decision follows a mandatory audit tender process required for public interest entities every ten years. The appointment will coincide with the mandatory lead audit partner rotation and requires shareholder approval at the company's 2026 Annual General Meeting.
The clinical-stage biopharmaceutical company, headquartered in London with US subsidiaries in New York City, focuses on developing treatments for blood and autoimmune diseases. The audit tender process was overseen by the Audit Committee, with detailed evaluation criteria to be disclosed in the Group's 2025 Annual Report & Accounts.
Hemogenyx Pharmaceuticals (LSE: HEMO) ha annunciato la decisione di riconfermare PKF Littlejohn LLP come revisore esterno per l'esercizio chiuso a dicembre 2025 e per gli anni successivi. La scelta segue la procedura obbligatoria di gara per le società di interesse pubblico, prevista ogni dieci anni. La nomina coinciderà con la rotazione obbligatoria del partner responsabile della revisione e dovrà essere approvata dagli azionisti nell'Assemblea Generale 2026.
La società biofarmaceutica in fase clinica, con sede a Londra e filiali negli Stati Uniti a New York, è focalizzata sullo sviluppo di terapie per malattie del sangue e autoimmuni. La gara di revisione è stata supervisionata dal Comitato per la Revisione, e i criteri di valutazione dettagliati saranno pubblicati nel Bilancio Annuale del Gruppo 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO) ha anunciado su decisión de volver a nombrar a PKF Littlejohn LLP como auditor externo para el ejercicio que termina en diciembre de 2025 y los años siguientes. La decisión se produce tras un concurso de auditoría obligatorio para entidades de interés público, que se realiza cada diez años. El nombramiento coincidirá con la rotación obligatoria del socio principal de auditoría y requerirá la aprobación de los accionistas en la Junta General de 2026.
La compañía biofarmacéutica en fase clínica, con sede en Londres y filiales en Estados Unidos en Nueva York, se centra en desarrollar tratamientos para enfermedades sanguíneas y autoinmunes. El proceso de concurso fue supervisado por el Comité de Auditoría, y los criterios de evaluación detallados se incluirán en las Cuentas Anuales del Grupo de 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO)는 2025년 12월로 끝나는 회계연도 및 그 이후에 대해 외부 감사인으로 PKF Littlejohn LLP를 재선임하기로 결정했다고 발표했습니다. 이 결정은 공공적 관심사에 해당하는 기업에 대해 10년마다 요구되는 의무적 감사 입찰 절차에 따른 것입니다. 이번 선임은 주감사 파트너의 의무적 교체와 동시에 이루어지며, 2026년 연례주주총회에서 주주 승인이 필요합니다.
런던에 본사를 두고 뉴욕에 미국 자회사를 둔 임상 단계의 바이오제약 회사인 이 기업은 혈액 및 자가면역 질환 치료제 개발에 주력하고 있습니다. 감사 입찰 절차는 감사위원회가 감독했으며, 상세한 평가 기준은 그룹의 2025년 연례 재무보고서에 공개될 예정입니다.
Hemogenyx Pharmaceuticals (LSE: HEMO) a annoncé sa décision de reconduire PKF Littlejohn LLP en tant qu'auditeur externe pour l'exercice clos en décembre 2025 et au-delà. Cette décision fait suite à une procédure d'appel d'offres obligatoire pour les entités d'intérêt public, réalisée tous les dix ans. Cette nomination coïncidera avec la rotation obligatoire du partenaire principal d'audit et devra être approuvée par les actionnaires lors de l'assemblée générale 2026.
La société biopharmaceutique en phase clinique, dont le siège est à Londres et qui possède des filiales aux États-Unis à New York, se concentre sur le développement de traitements pour les maladies du sang et auto-immunes. La procédure d'appel d'offres a été supervisée par le comité d'audit ; les critères d'évaluation détaillés seront publiés dans les comptes annuels du groupe 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO) hat beschlossen, PKF Littlejohn LLP als externen Abschlussprüfer für das am Dezember 2025 endende Geschäftsjahr und darüber hinaus erneut zu bestellen. Die Entscheidung folgt auf ein verpflichtendes Ausschreibungsverfahren für Prüfungen bei Unternehmen von öffentlichem Interesse, das alle zehn Jahre durchzuführen ist. Die Bestellung fällt mit der verpflichtenden Rotation des leitenden Prüfungspartners zusammen und bedarf der Zustimmung der Aktionäre auf der Hauptversammlung 2026.
Das klinisch orientierte Biopharmaunternehmen mit Sitz in London und US-Niederlassungen in New York konzentriert sich auf die Entwicklung von Therapien für Blut- und Autoimmunerkrankungen. Das Ausschreibungsverfahren wurde vom Prüfungsausschuss überwacht; die detaillierten Bewertungskriterien werden im Jahresabschlussbericht der Gruppe 2025 veröffentlicht.
- None.
- None.
LONDON, UK / ACCESS Newswire / August 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory auditor, it intends to re-appoint PKF Littlejohn LLP as external auditor for the financial year ending December 2025 onwards. This will coincide with the timing of the mandatory lead audit partner rotation.
The audit tender was conducted as a result of the requirement for public interest entities to undertake an audit tender at least every ten years. A thorough tender process, overseen by the Audit Committee, was undertaken and this proposed change of auditor follows a recommendation by the Audit Committee to the Board based on the outcome of the tender process.
Further details of the audit tender process and evaluation criteria will be included in the Group's 2025 Annual Report & Accounts. The appointment will be subject to shareholder approval at the Company's 2026 Annual General Meeting.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
When will PKF Littlejohn LLP begin their role as Hemogenyx Pharmaceuticals' (HOPHF) external auditor?
Why did Hemogenyx Pharmaceuticals (HOPHF) conduct an audit tender process?
What does Hemogenyx Pharmaceuticals (HOPHF) specialize in?
Where will shareholders find details about the audit tender process?
